{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=78",
    "query": {
      "intervention": "Control Study Product",
      "page": 78
    },
    "page_size": 10
  },
  "pagination": {
    "page": 78,
    "page_size": 10,
    "total_count": 4242,
    "total_pages": 425,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=79&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=77&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T01:23:10.015Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06267729",
      "title": "Study of AZD0754 in Participants With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AZD0754",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD2287",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2024-03-12",
      "completion_date": "2026-11-24",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06267729"
    },
    {
      "nct_id": "NCT02725957",
      "title": "A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Subjects"
      ],
      "interventions": [
        {
          "name": "Trehalose for IV Infusion",
          "type": "DRUG"
        },
        {
          "name": "Saline 0.9% IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioblast Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-03",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725957"
    },
    {
      "nct_id": "NCT02647853",
      "title": "Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nasolabial Folds",
        "Lipoatrophy",
        "Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "TAT4 Gel concentration A",
          "type": "DRUG"
        },
        {
          "name": "TAT4 Gel concentration B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Topokine Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2014-10",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-06",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647853"
    },
    {
      "nct_id": "NCT02533505",
      "title": "Phase IV O2 Consumption Study in COPD Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo pMDI 160/4.5 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2015-08-25",
      "completion_date": "2016-08-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-30",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 5,
      "location_summary": "Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02533505"
    },
    {
      "nct_id": "NCT06901505",
      "title": "To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia of Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Erythropoiesis-Stimulating Agent (ESA)",
          "type": "DRUG"
        },
        {
          "name": "Vadadustat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2025-07-24",
      "completion_date": "2026-08-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 18,
      "location_summary": "Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06901505"
    },
    {
      "nct_id": "NCT03535129",
      "title": "A Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Alcohol Drinking Related Problems",
        "Alcohol-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Real time fMRI neurofeedback",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 101,
      "start_date": "2018-09-20",
      "completion_date": "2025-03-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03535129"
    },
    {
      "nct_id": "NCT00633945",
      "title": "Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cutaneous Lupus Erythematosus (CLE)"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 5,
      "start_date": "2007-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00633945"
    },
    {
      "nct_id": "NCT02297412",
      "title": "Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Pain",
        "Breast Carcinoma",
        "Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Minocycline Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2014-11",
      "completion_date": "2016-07-08",
      "has_results": true,
      "last_update_posted_date": "2022-01-31",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 12,
      "location_summary": "Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more",
      "locations": [
        {
          "city": "Pismo Beach",
          "state": "California"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02297412"
    },
    {
      "nct_id": "NCT00137969",
      "title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 262,
      "start_date": "2005-05-10",
      "completion_date": "2008-08-25",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 63,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00137969"
    },
    {
      "nct_id": "NCT01982253",
      "title": "Fasiglifam 25 mg BID vs 50 mg QD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Fasiglifam",
          "type": "DRUG"
        },
        {
          "name": "Placebo to fasiglifam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-10",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-11-04T01:23:10.015Z",
      "location_count": 47,
      "location_summary": "Goodyear, Arizona • Long Beach, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01982253"
    }
  ]
}